Tirzepatide (pre-filed pen) Hilma Biocare
Tirzepatide (Pre-Filled Pen) by Hilma Biocare is a ready-to-use injectable in a convenient 3 ml pen holding 10 mg of the peptide, a next-generation weight-management and metabolic agent. Unlike single-agonist drugs, Tirzepatide is a dual agonist of both the GIP and GLP-1 receptors, and that combined action delivers stronger appetite suppression and better blood-sugar control than GLP-1 alone. The pre-filled pen removes any preparation, giving precise, consistent weekly dosing straight from the device.
| Active substance | Tirzepatide (GIP/GLP-1 dual agonist) |
| Manufacturer | Hilma Biocare |
| Strength | 10 mg per pen (3 ml) |
| Form | Pre-filled pen |
| Typical dosage | Titrated weekly (start low) |
| Focus | Weight loss, glucose control |
Effects and benefits
By hitting two incretin receptors at once, Tirzepatide produces powerful appetite control, improved insulin response and significant, sustained weight loss — results that in trials have exceeded single-agonist GLP-1 drugs. The pen format makes it one of the easiest ways to run a precise weekly protocol.
- Strong appetite and craving control
- Improved glycemic control
- Significant, sustained weight loss
- Ready-to-use pen, precise dosing
Usage and administration
Tirzepatide is injected subcutaneously once weekly, always starting at a low dose and titrating up slowly to manage nausea and GI effects. As a metabolic agonist it belongs alongside the rest of the peptides range rather than in a performance cycle.
Related products
Those comparing GLP-1 options often look at the single-agonist Semaglutide as a gentler start, or the triple-agonist Retatrutide for even stronger effects.
Why choose Hilma Biocare
Every pen is produced to consistent pharmaceutical standards with dependable dosing you can trust. Explore the full Hilma Biocare catalogue for matching metabolic products.
| Characteristics | |
| Shelf Life | 36 months from manufacture date |
| Drug Class | GLP-1/GIP Receptor Agonist |
| Concentration | 10 mg per pen |
| Half-Life | Approximately 5 days |
| Detection Time | Not typically tested |
| Active Half-Life | Approximately 5 days (117–120 hours) |
| Active Ingredient | Tirzepatide |
| Active Substance | Tirzepatide |
| Dosage | 10mg |
| Drug Category | Weight Management |
| Form | Injectable solution |
| Product Packaging | Pre-filled injection pen |
| Water Retention | None |
| Liver Toxicity | None |
| Chemical Structure | Synthetic dual-agonist peptide |